Publications by authors named "Deborah Keefe"

Claim this Profile
C
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Deborah Keefe

Lancet Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study.
Julie Kanter, Sarah Mennito, Santosh M Nair, Deepa Manwani, Abdullah Kutlar, Deborah Keefe

Ther Adv Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Xiaoling Wei, Anna Passera, Elisa Muscianisi, Lorenz Uhlmann, Li Chen, Deborah Keefe

J Am Acad Dermatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Michael Sticherling, Arjen F Nikkels, Ashraf M Hamza, Pearl Kwong, Jacek C Szepietowski, Deborah Keefe

Am J Clin Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Alexa B Kimball, Gregor B E Jemec, Afsaneh Alavi, Ziad Reguiai, Alice B Gottlieb, Deborah Keefe

Lancet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Deborah Keefe

Paediatr Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Deborah Keefe

Br J Dermatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Bardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, Isaak Effendy, Waldemar Placek, Deborah Keefe

J Dermatolog Treat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, Xenofon Baraliakos, Kristian Reich, Deborah Keefe

Acta Derm Venereol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Bardur Sigurgeirsson, John Browning, Stephen Tyring, Jacek C Szepietowski, Raquel Rivera-Díaz, Deborah Keefe

Dermatol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Deborah Keefe

J Am Acad Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Rudolf A de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe

Br J Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Koutaro Yokote, Misako Sano, Isao Tsumiyama, Deborah Keefe

Diabetes Obes Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe

Obesity (Silver Spring)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension.
Janice E Sullivan, Deborah Keefe, Yinong Zhou, Lisa Satlin, Hui Fang

Clin Pediatr (Phila)· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study.
Giuseppe Villa, Stephanie Le Breton, Ghionul Ibram, Deborah L Keefe

J Clin Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihypertensive treatment in patients with class 3 obesity.
Jens Jordan, Sam W Boye, Stephanie Le Breton, Deborah L Keefe, Stefan Engeli

Ther Adv Endocrinol Metab· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.
Amil M Shah, Sung Hee Shin, Madoka Takeuchi, Hicham Skali, Akshay S Desai, Deborah Keefe

Eur J Heart Fail· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
Jun-Ren Zhu, Ning-Ling Sun, Kan Yang, Jian Hu, Geng Xu, Deborah Keefe

Hypertens Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Domenic Sica, Alan H Gradman, Ole Lederballe, Rainer E Kolloch, Jack Zhang, Deborah L Keefe

Clin Drug Investig· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Raymond R Townsend, Alan D Forker, Vaishali Bhosekar, Anthony Yadao, Deborah L Keefe

J Clin Hypertens (Greenwich)· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.
William B White, Robert Bresalier, Allen P Kaplan, Biff F Palmer, Robert H Riddell, Deborah L Keefe

J Clin Hypertens (Greenwich)· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Venkateswar Jarugula, Ching-Ming Yeh, Dan Howard, Christopher Bush, Deborah L Keefe

J Clin Pharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Karl Andersen, Myron H Weinberger, Brent Egan, Christian M Constance, Melanie Wright, Deborah L Keefe

Cardiovasc Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.
William B White, Robert Bresalier, Allen P Kaplan, Biff F Palmer, Robert H Riddell, Deborah L Keefe

J Clin Hypertens (Greenwich)· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis